"BRAF mutation testing for patients diagnosed with stage III or stage I" by Richard A. Scolyer, Victoria Atkinson et al.
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation testing an important step in the management of patients diagnosed with stage III or IV melanoma; one that can help better ensure that the optimal choice of systemic treatment is initiated with minimal delay. This article offers guidance about when and how BRAF mutation testing should be conducted ...
United States American Joint Committee On Cancer Union For International Cancer Control American Joint Committee International Cancer Control Raf Mutation Testing
Source: uow.edu.au